MPT Real Estate

Medical Properties Trust, Inc.

$2.02-7.34%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Real Estate
Industry: REIT - Healthcare Facilities
Country: United States
Market cap: 1.2B USD
Enterprise value: 11.1B USD
Full-time employees: 121

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.49 vs a peer median of 0.75) and more debt relative to equity (2.16× vs a peer median of 0.80×)higher risk: bigger price swings (beta 1.49 vs peers 0.75) and more debt vs equity (2.16× vs peers 0.80×)

Ranks #452 of 632 real estate companies (bottom 29%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 85% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Medical Properties Trust looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Medical Properties Trust reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
More volatile share price. Beta 1.49: tends to move more than the market.
Medical Properties Trust's shares have swung more with the market than most peers' (beta 1.49, above the market's 1.0).

StockQuotient Score

41/ 100▲ 2 since Oct 27 close

Oct 5 38 → Nov 4 41 (+3)

Valuation

Is the price right?

77/100

Moderate▲ 5 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 72 → 77

Share price -25.7%+12
Company's reported figures updated-7

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ FCF yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-2.5%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.10Sector median: 0.0535 · MAD: 0.0484

EBITDA yield9.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 1.80Sector median: 0.0536 · MAD: 0.0204

Free cash flow yield18.8%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingReported value20% base weight · Z-score 2.77Sector median: 0.0650 · MAD: 0.0444

Other data (not scored)

Book yield372.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 1.1277 · MAD: 0.5490

Growth

Is it growing?

40/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.28Sector median: 0.1117 · MAD: 0.3101

3-year revenue growth-10.5%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -1.91Sector median: 0.0378 · MAD: 0.0744

Revenue growth10.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.82Sector median: 0.0297 · MAD: 0.0927

Profitability

Does it earn well?

38/100

Weak▲ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Net margin rose 9.6 points to -3.0%

Why it changed since the Oct 27, 2026 close: Score 37 → 38

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin55.5%

Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Reported value33% base weight · Z-score 1.27Sector median: 0.2683 · MAD: 0.2257

Return on assets-0.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.72Sector median: 0.0211 · MAD: 0.0134

Return on invested capital3.6%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsReported value33% base weight · Z-score 0.11Sector median: 0.0341 · MAD: 0.0197

Other data (not scored)

Gross margin90.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.5380 · MAD: 0.2259

Return on equity-0.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0521 · MAD: 0.0465

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.49

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.27Sector median: 0.7490 · MAD: 0.3270

Current ratio1.17×

Yahoo Finance fallback · SEC figure unavailable or out of dateReported value33% base weight · Z-score -0.03Sector median: 1.1950 · MAD: 0.7210

Debt / equity2.16×

SEC filings · latest balance sheetReported value33% base weight · Z-score -3.48Sector median: 0.8040 · MAD: 0.3893

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Medical Properties Trust

Is Medical Properties Trust getting weaker?: Its latest SEC filing (Aug 10, 2026) got stronger: net margin rose 9.6 points to -3.0%. Its overall score is 41/100, up 2 since Oct 28, 2026.
How is Medical Properties Trust valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 77/100 against 762 real estate peers. Free cash flow yield 18.8% vs a peer median of 6.5% (stronger than 85% of peers).Free cash flow yield 18.8% vs peers 6.5% (stronger than 85% of peers). Earnings yield -2.5% vs a peer median of 5.3% (weaker than 100% of peers).Earnings yield -2.5% vs peers 5.3% (weaker than 100% of peers).
Is Medical Properties Trust growing?: At about the same pace as its peers. Growth scores 40/100 against 762 real estate peers. Revenue growth 10.6% vs a peer median of 3.0% (stronger than 72% of peers).Revenue growth 10.6% vs peers 3.0% (stronger than 72% of peers). 3-year revenue growth -10.5% vs a peer median of 3.8% (weaker than 83% of peers).3-year revenue growth -10.5% vs peers 3.8% (weaker than 83% of peers).
How profitable is Medical Properties Trust?: Less profitable than most of its peers. Profitability scores 38/100 against 762 real estate peers. Operating margin 55.5% vs a peer median of 26.8% (stronger than 76% of peers).Operating margin 55.5% vs peers 26.8% (stronger than 76% of peers). Return on assets -0.2% vs a peer median of 2.1% (weaker than 84% of peers).Return on assets -0.2% vs peers 2.1% (weaker than 84% of peers).
How risky is Medical Properties Trust?: Higher risk relative to 762 real estate peers, judged on debt, liquidity and share-price swings. Beta 1.49 vs a peer median of 0.75 (weaker than 94% of peers).Beta 1.49 vs peers 0.75 (weaker than 94% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 10, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Net margin rose 9.6 points to -3.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.0B USD	1.0B USD	+1.9%
Net income (12 months)	−125.9M USD	−30.1M USD	−76.1%
Debt	9.7B USD	9.7B USD	+0.4%
Cash	425.0M USD	396.6M USD	−6.7%
Shares outstanding	598.1M	597.2M	−0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Sector: Real Estate · 124 companies

Valuations in Real Estate are within their usual range since 2016.

30% of months since 2016 were valued lower than now.
15% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +4% and earnings +25% (medians): earnings grew faster than prices.
Median price-to-sales is +112% vs the whole market, against a usual +154%.

2016Shaded: most expensive fifth of its range2026

Shown for Real Estate: too few REIT - Healthcare Facilities companies have a long enough history of their own.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	93.4%	89.1%	87.4%	92.6%	90.7%	▼ 1.8 pts
Operating margin	43.5%	41.8%	-37.8%	-3.1%	3.0%	▲ 6.1 pts
Net margin	42.5%	58.5%	-63.8%	-242.1%	-28.5%	▲ 214 pts
Return on assets (ROA)	3.2%	4.6%	-3.0%	-16.9%	-1.8%	▲ 15 pts
Return on equity (ROE)	7.8%	10.5%	-7.3%	-49.9%	-6.0%	▲ 44 pts
Debt to equity	1.34×	1.19×	1.32×	1.83×	2.11×	▲ 15%
Interest coverage	1.83×	1.80×	-0.80×	-0.07×	0.06×	▲ 178%

MPT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

Dear Life Co.,Ltd.3245.T95/ 100

Sakura Development Co.,Ltd2539.TW94/ 100

Millrose Properties, Inc.MRP94/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.49 vs a peer median of 0.75) and more debt relative to equity (2.16× vs a peer median of 0.80×)higher risk: bigger price swings (beta 1.49 vs peers 0.75) and more debt vs equity (2.16× vs peers 0.80×)

Ranks #452 of 632 real estate companies (bottom 29%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 85% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Medical Properties Trust looks cheaper than 85% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Medical Properties Trust reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

More volatile share price. Beta 1.49: tends to move more than the market.

Medical Properties Trust's shares have swung more with the market than most peers' (beta 1.49, above the market's 1.0).

Questions investors ask about Medical Properties Trust

Is Medical Properties Trust getting weaker?

Its latest SEC filing (Aug 10, 2026) got stronger: net margin rose 9.6 points to -3.0%. Its overall score is 41/100, up 2 since Oct 28, 2026.

How is Medical Properties Trust valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 77/100 against 762 real estate peers. Free cash flow yield 18.8% vs a peer median of 6.5% (stronger than 85% of peers).Free cash flow yield 18.8% vs peers 6.5% (stronger than 85% of peers). Earnings yield -2.5% vs a peer median of 5.3% (weaker than 100% of peers).Earnings yield -2.5% vs peers 5.3% (weaker than 100% of peers).

Is Medical Properties Trust growing?

At about the same pace as its peers. Growth scores 40/100 against 762 real estate peers. Revenue growth 10.6% vs a peer median of 3.0% (stronger than 72% of peers).Revenue growth 10.6% vs peers 3.0% (stronger than 72% of peers). 3-year revenue growth -10.5% vs a peer median of 3.8% (weaker than 83% of peers).3-year revenue growth -10.5% vs peers 3.8% (weaker than 83% of peers).

How profitable is Medical Properties Trust?

Less profitable than most of its peers. Profitability scores 38/100 against 762 real estate peers. Operating margin 55.5% vs a peer median of 26.8% (stronger than 76% of peers).Operating margin 55.5% vs peers 26.8% (stronger than 76% of peers). Return on assets -0.2% vs a peer median of 2.1% (weaker than 84% of peers).Return on assets -0.2% vs peers 2.1% (weaker than 84% of peers).

How risky is Medical Properties Trust?

Higher risk relative to 762 real estate peers, judged on debt, liquidity and share-price swings. Beta 1.49 vs a peer median of 0.75 (weaker than 94% of peers).Beta 1.49 vs peers 0.75 (weaker than 94% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.0B USD

1.0B USD

+1.9%

Net income (12 months)

−125.9M USD

−30.1M USD

−76.1%

Debt

9.7B USD

9.7B USD

+0.4%

Cash

425.0M USD

396.6M USD

−6.7%

Shares outstanding

598.1M

597.2M

−0.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

93.4%

89.1%

87.4%

92.6%

90.7%

▼ 1.8 pts

Operating margin

43.5%

41.8%

-37.8%

-3.1%

3.0%

▲ 6.1 pts

Net margin

42.5%

58.5%

-63.8%

-242.1%

-28.5%

▲ 214 pts

Return on assets (ROA)

3.2%

4.6%

-3.0%

-16.9%

-1.8%

▲ 15 pts

Return on equity (ROE)

7.8%

10.5%

-7.3%

-49.9%

-6.0%

▲ 44 pts

Debt to equity

1.34×

1.19×

1.32×

1.83×

2.11×

▲ 15%

Interest coverage

1.83×

1.80×

-0.80×

-0.07×

0.06×

▲ 178%